Share Prices & Company Research

Market News

16 Jul 2021 | 13:42

GSK announces positive results for treatment of anaemia in CDK patients

(Sharecast News) - GlaxoSmithKline announced positive headline results from studies into its treatment of patients suffering from anaemia due to chronic kidney disease, Daprodustat. In particular, GSK's chief scientific officer, Hal Barron, highlighted the results from the ASCEND-ND and ASCEND-D studies given the need to manage cardiovascular outcomes for such patients and the convenience of oral treatments.

"We will continue to analyse the data from the robust phase 3 ASCEND programme and look forward to working closely with regulators as we plan for our submissions," Barron added.

Each of the five studies in GSK's third phase ASCEND programme met their respective primary or co-primary endpoints.

The company also noted that Daprodustat was "generally" well-tolerated in both non-dialysis and dialysis patients.

Thus far Daprodustat had only been approved by for use by Japanese authorities in patients with renal anaemia.

ASCEND had enrolled more than 8,000 patients who were treated for up to 3.75 years.

As of 1349 BST, shares of GSK were trading higher by 0.60% at 1,415.4p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.